Search

Your search keyword '"Newlands, Edward"' showing total 194 results
Start Over Author "Newlands, Edward"
194 results on '"Newlands, Edward"'

28. Unusual case of choriocarcinoma occurring 12 months after delivery

Author

Todd, Anthony, Newlands, Edward, and Palazzo, Mark

Subjects
Chorionic gonadotropin -- Health aspects, Hydatidiform mole -- Risk factors -- Diagnosis, Pregnancy, Complications of -- Health aspects -- Diagnosis -- Risk factors, Choriocarcinoma -- Diagnosis -- Risk factors, Pregnancy, Molar -- Risk factors -- Diagnosis, Health, Diagnosis, Risk factors, Health aspects
Abstract

Choriocarcinoma should be considered in women of childbearing age with acute haemorrhage occurring even years after a normal birth Choriocarcinoma is a malignant tumour that arises from trophoblastic epithelium; it [...]

Published
1998

33. O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

Author

Alan Hilary Calvert, Siow Ming Lee, Mark R Middleton, David R. Newell, N M Bleehen, Stephen R. Wedge, Newlands Edward Stuart, G. J. S. Rustin, Geoffrey P. Margison, J M Lunn, Nick Thatcher, M. H. Brampton, Charles Q Morris, and Michael J. Lind

Subjects
Adult, Male, Cancer Research, Pathology, medicine.medical_specialty, Methyltransferase, Biopsy, DNA methyltransferase, O(6)-Methylguanine-DNA Methyltransferase, In vivo, Predictive Value of Tests, medicine, Temozolomide, Humans, Prospective Studies, neoplasms, Antineoplastic Agents, Alkylating, Melanoma, business.industry, Middle Aged, medicine.disease, In vitro, digestive system diseases, Dacarbazine, Oncology, Lymphatic Metastasis, Cancer research, Leukocytes, Mononuclear, Female, Lymph, business, Progressive disease, medicine.drug, Research Article
Abstract

Resistance of tumour cells to methylating and monochloroethylating agents in vitro and in vivo has been linked to levels of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). In a clinical trial of temozolomide in advanced malignant melanoma, the relationship between pretreatment MGMT levels in biopsies of cutaneous tumours and involved lymph nodes and clinical response to the drug has been studied. Among 50 evaluable patients, there were three complete responses (CR), four partial responses (PR), six with stable disease (SD) and 37 with progressive disease (PD), with an overall response rate of 14%. In 33 patients in whom MGMT level and clinical response could be evaluated, the tumour MGMT levels (fmol mg(-1) protein) were: CR, 158 +/- 119; PR, 607 +/- 481; NC, 171 +/- 101; PD, 185 +/- 42.3. Thus, measurements of pretreatment levels of MGMT in melanoma did not predict for response to temozolomide.

Published
1998

34. Familial recurrent hydatidiform mole:a review

Author

Fisher, Rosemary A., Hodges, Matt, Newlands, Edward S., Fisher, Rosemary A., Hodges, Matt, and Newlands, Edward S.

Abstract

This article reviews published data on familial recurrent hydatidiform mole with particular reference to the genetic basis of this condition, the likely outcome of subsequent pregnancies in affected women and the risk of persistent trophoblastic disease following molar pregnancies in these families. Familial recurrent hydatidiform mole is characterized by recurrent complete hydatidiform moles of biparental, rather than the more usual androgenetic, origin. Although the specific gene defect in these families has not been identified, genetic mapping has shown that in most families the gene responsible is located in a 1.1 Mb region on chromosome 19q13.4. Mutations in this gene result in dysregulation of imprinting in the female germ line with abnormal development of both embryonic and extraembryonic tissue. Subsequent pregnancies in women diagnosed with this condition are likely to be complete hydatidiform moles. In 152 pregnancies in affected women, 113 (74%) were complete hydatidiform moles, 26 (17%) were miscarriages, 6 (4%) were partial hydatidiform moles, and 7 (5%) were normal pregnancies. Molar pregnancies in women with familial recurrent hydatidiform mole have a risk of progressing to persis-tent trophoblastic disease similar to that of androgenetic complete hydatidiform mole.

Published
2004

35. Utility of commonly used commercial human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic diseases.

Author

Cole, Laurence A., Shahabi, Shohreh, Butler, Stephen A., Mitchell, Hugh, Newlands, Edward S., Behrman, Harold R., Verrill, Harland L., Cole, Laurence A., Shahabi, Shohreh, Butler, Stephen A., Mitchell, Hugh, Newlands, Edward S., Behrman, Harold R., and Verrill, Harland L.

Abstract

A multi-centre study involving worldwide collaboration highlighted the between-method variation in hCG quantification and estimation and the resultant potential misdiagnosis of GTD.

Published
2001

Catalog

Books, media, physical & digital resources
See catalog results